anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Elderly patients (aged 65 years or older) may have increased sensitivity to Butorphanol Tartrate Nasal Spray. 

Of the approximately 1700 patients treated with Butorphanol Tartrate Nasal Spray in clinical studies, 8% were 65 years of age or older and 2% were 75 years or older. 

Due to changes in clearance, the mean half-life of butorphanol is increased by 25% (to over 6 hours) in patients over the age of 65 years [see CLINICAL PHARMACOLOGY: Pharmacokinetics]. Elderly patients may be more sensitive to the side effects of butorphanol. In clinical studies of Butorphanol Tartrate Nasal Spray, elderly patients had an increased frequency of headache, dizziness, drowsiness, vertigo, constipation, nausea and/or vomiting, and nasal congestion compared with younger patients. There are insufficient efficacy data for patients ≥65 years to determine whether they respond differently from younger patients. 

Initially a 1 mg dose of Butorphanol Tartrate Nasal Spray should be generally used in geriatric patients and 90 to 120 minutes should elapse before administering a second 1 mg does, if needed [see CLINICAL PHARMACOLOGY: Individualization of Dosage]. 

In general, use caution when selecting a dosage for an elderly patient, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy [see DOSAGE AND ADMINISTRATION]. 

Respiratory depression is the chief risk for elderly patients treated with opioids, and has occurred after large initial doses were administered to patients who were not opioid-tolerant or when opioids were coadministered with other agents that depress respiration. Titrate the dosage of Butorphanol Tartrate Nasal Spray slowly in geriatric patients and frequently reevaluate the patient for signs of central nervous system and respiratory depression [see WARNINGS]. 

This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to the new chemical compound - 3-benzylaminomethylenepyrrolidine-2,4-dione. Compound shows the more expressed anticonvulsant activity, broad spectrum of action and decreased toxicity as compared with the known anticonvulsant preparation widely used in clinics. Invention describes also the drug eliciting anticonvulsant effect. EFFECT: new compound indicated above, improved properties of compound. 3 cl, 12 tbl, 1 ex
Nanoparticulate carrier formulations are useful to solubilize, deliver, and target hydrophobic drugs for treating diseases including cancer and bacterial infections. The formulations contain amphiphilic peptides having a hydrophobic portion and a positively charged hydrophilic portion. The peptides self-associate at nonacidic pH to form micelles with a spherical nanoparticle morphology. The hydrophobic core of the nanoparticles encapsulates hydrophobic drugs, including antitumor agents, increasing their solubility in water and allowing them to be targeted, for example, to cancer cells. The positively charged surface of the nanoparticles, together with an optional targeting moiety such as an RGD peptide, allows the nanoparticles to bind selectively to mammalian cells and bacterial cells, including cancer cells that overexpress integrin receptors. The pH-dependence of the nanoparticle association/dissociation can be employed to conveniently load the nanoparticles with hydrophobic drug using a controlled pH shift, and unload them in acidic intracellular compartments. The ability of the carrier formulations to solubilize and target hydrophobic drugs gives rise to strategies for the selective inhibition or killing of cancer cells, such as the killing of osteosarcoma cells using the drug curcumin. The amphiphilic peptides and nanoparticles derived therefrom also give rise to additional compositions and methods that have useful bacteriocidal features as well as the ability to promote cell adhesion in cell scaffolds and coatings for medical implants.
The invention discloses a candle with healthcare function on lymph. The candle contains the following raw materials by weight percent: 89 percent of 58 percent mineral wax, 3 percent of polyethylene wax, 3 percent of soft wax, 3 percent of purely natural oilbanum oil and 2 percent of kirilow groundsel herb. The candle can be used for illumination and has healthcare function on lymph. Two percent of kirilow groundsel herb extract is extracted by using 60 percent ethanol and then is proportioned and evenly mixed with other raw materials. When the candle is combusted, the purely natural oilbanum oil and the kirilow groundsel herb volatilize fragrance in the ambient air, so the healthcare function on the lymph is obtained. When in production, common wax is wrapped on the outer layer of the candle, so the candle can be stored for long time and the purely natural oilbanum oil is not evaporated and wasted.
Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR or PR receive 2 additional courses beyond CR or PR.
The purpose of this study is to investigate attitudes concerning the Measles, Mumps, \& Rubella (MMR) vaccine among adult parents in the United States. Attitudes will be assessed via a web-based survey administered by Survey Sampling International (SSI). Project sample size is 1,000, all to be recruited by SSI. The survey will take no more than 20-30 minutes to complete. The survey questions and response options attached. With the exception of demographic questions (e.g., age, sex, race) at the end of the survey, questions will not be able to be "skipped" because 1) the survey questions primarily assess attitudes and beliefs, 2) the questions are not of a sensitive nature, 3) responses are anonymous, 4) respondents have indicated their desire and willingness to respond to surveys like this by virtue of their enrollment as an SSI panel member, 5) there is no pressure for respondents to complete the survey, 6) respondents may cease responding to the survey at any time after they begin.

Respondents will be asked to provide information about their children's ages and sex, as well as historical recall information about their past vaccine decisions for their child/children. All respondents will receive general information from the Centers for Disease Control and Prevention (CDC) regarding MMR and the MMR vaccine (taken from the CDC's Vaccine Information Sheet), followed by summarized information about MMR and the MMR vaccine. A quarter of respondents will receive only this information. The other three-quarters of respondents will also receive additional "benefit" information that either underscores: a) the MMR vaccine's benefit to the child who receives it, b) the MMR vaccine's benefits to society as a whole, or c) the MMR vaccine's benefit to both the child who receives it as well as to society as a whole. The purpose of this additional "benefit" information (which will randomly vary among respondents) is to compare people's attitudes when they're given this information about the MMR vaccine's benefit to people's attitudes when they receive the general information. This information is noted in the attached survey, and mimics the information that parents are typically given in clinic settings regarding MMR and the MMR vaccine. The purpose of this study is to systematically assess people's responses to this information, which is already offered in clinical settings and is publicly available via the CDC.
The object of the investigation relates to the function named Sleep Apnea Monitoring or SAM function. This function is part of the REPLY 200 DR pacemakers, whose intended use is cardiac pacing. Sleep Apnea Syndrom (SAS) causes serious social and economic problems, not only because of its high prevalence but also because it is associated with increased cardiovascular morbidity and mortality.

Patients with Sleep Apnea often have arterial and pulmonary hypertension, a high risk of coronary artery disease, and heart failure, whereas a high percentage of patients show heart rhythm disturbances. In addition, these patients are at increased risk of being involved in traffic accidents, as well as suffering a decline in their family, social, and professional lives. Therefore, the prompt diagnosis of these patients could be of great importance. Today the gold standard for the diagnosis of SAS is overnight polysomnography (PSG) in a sleep laboratory. However, the shortage of sleep laboratories and the high cost of PSG render this method inadequate for widespread screening. For these reasons, in recent years, there have been attempts to develop alternative diagnostic with a view to simplify the diagnosis.

Thanks to the feature SAM included in the pacemaker, sequences of respiratory cycles are analyzed to detect, to count and to report abnormal breathing events during the night. This analysis is based on the Minute Ventilation (MV) signal. The MV signal represents the real time expansion/contraction of the thorax of the patient. It is derived of the transthoracic impedance periodic measurements. The device is able to provide the physician with day-by-day Respiratory Disturbance Index (RDI) equal to the sum of events divided by the number of hours per night. Physician will also access to the total number of events over the previous night presented per hour.
<P>PROBLEM TO BE SOLVED: To provide a remote diagnostic reading system capable of efficiently selecting a suitable diagnostic reading doctor according to inspection contents while considering status information and qualitative evaluation.  <P>SOLUTION: A diagnostic reading doctor 7 registered in the remote diagnostic reading system 1 registers basic information for a diagnostic reading doctor 29 including expertise information in a diagnostic reading center 3. The diagnostic reading doctor 7 regularly transmits the status information (status 33) to the diagnostic reading center 3. A medical clinic 5 as a client for diagnostic reading requests diagnostic reading of image data 25 obtained by a modality 11 to the diagnostic reading center 3 with diagnostic reading conditions 23 (emergency priority, contents priority, fields or the like). The diagnostic reading center 3 selects a diagnostic reading doctor 7 coincided with the diagnostic reading conditions 23 by further considering conditions such as basic information 31 for determination and a status 33. A diagnostic reading report 37 of the diagnostic reading doctor 7 is transmitted to the medical office 5 as a client via the diagnostic reading center 3. The medical clinic 5 transmits evaluation results 43 of the report 37 to the diagnostic reading center 3, and the evaluation results 43 are reflected on updating of the basic information 31 for determination.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Retinitis Pigmentosa (RP) is a disease in which one of several different mutations differentially causes degeneration of rod photoreceptors while sparing cone photoreceptors. The loss of rod photoreceptors results in poor vision in dim illumination (night blindness), but does not affect most activities of daily life including reading or driving. However, after most rod photoreceptors are eliminated, cone photoreceptors begin to die, resulting in gradual constriction of visual fields which over time causes visual disability.

Rods outnumber cones by a ratio of 95:5 and therefore after mutation-induced degeneration of rods, the majority of cells in the outer retina have been eliminated, markedly reducing oxygen utilization. However, oxygen supply is unchanged resulting in a large excess of tissue oxygen surrounding cones. This results in progressive oxidative damage that contributes to slowly progressive degeneration of cone photoreceptors. N-acetylcysteine (NAC) is a strong antioxidant that is approved for acetaminophen overdose. Orally administered NAC in a mouse model of RP reduced oxidative damage to cones and promoted maintenance of function and survival of cones. In a phase I clinical trial in patients with RP, oral administration of NAC for 6 months was well-tolerated and resulted in a small but statistically significant improvement in visual acuity and light sensitivity in the retina. This suggests that long-term administration of NAC may promote survival and maintenance of function of cones. NAC Attack is a phase III, multicenter, randomized, placebo controlled trial that will determine if oral NAC provides benefit and is safe in patients with RP.
Eighty four patients were allocated to the study group. Due to expanded Kerr incisions 4 patients in study group did not receive their allocated intervention. In addition, 29 patients in the study group were lost to follow up and did not come to the sixth week check up. Statistical analysis is based on data from the remaining 51 study group.
Patients receive motexafin gadolinium IV over 5-10 minutes once daily (prior to radiotherapy) 5 days a week for 6 weeks. Patients undergo focal cranial radiotherapy once daily 5 days a week for 6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Up to 22 healthy children (5-8 years old) will be enrolled in a single-center, single-use, randomized, two-period, IRB approved cross-over study. Subjects will be randomly assigned to one of two treatment sequences: 1) brush two minutes with marketed children's manual toothbrush (MTB) or 2) brush 30 seconds with AutoBrush® 360° Sonic Toothbrush (AB) and fluoride toothpaste. Qualified subjects will have pre-brushing supragingival plaque levels ≥ 1.8 according to the Lobene-Soparkar Modified Turesky Modification of the Quigley-Hein Plaque Index (PI), following 12-16 hours plaque accumulation period. Under parent's supervision, subjects brushed at home with their assigned toothbrush, twice daily during a 2-day familiarization period. After refraining (12-16 hours) from oral hygiene, subjects returned for plaque assessment, supervised use of their assigned toothbrush and a post-brushing plaque evaluation. Subjects were given the second toothbrush to begin the next 2-day familiarization period and second period evaluation procedures. Analysis of covariance (ANCOVA) will be used for single-use brushing PI models to assess whole mouth and 8 other hard-to-reach tooth sites.
Participants undergo bronchoscopy over 30-60 minutes at baseline. Beginning 1 week after bronchoscopy, participants learn to use the SREC without nicotine for 2 weeks and switch completely to the SREC without nicotine starting day 15 for 8 weeks. Participants will be offered varenicline to aid cessation. Participants undergo a second bronchoscopy on day 71.
Participants will receive pembrolizumab 400 mg PLUS lenvatinib 20 mg. Pembrolizumab will be administered IV Q6W for up to 17 administrations (up to \~ 2 years). Lenvatinib will be administered orally QD until progressive disease or discontinuation.
PCT No. PCT/DE79/00001 Sec. 371 Date Jul. 31, 1979 Sec. 102(e) Date Jul. 31, 1979 PCT Filed Jan. 2, 1979.An improved opaque, photopolymerizable dental filling material is provided comprised of acrylic acid ester compounds containing mono and/or polyfunctional acrylic or methacrylic ester compounds, photoinitiators, pigments and possibly activators and silicon dioxide or silicate fillers, the improvement comprising the presence of finely divided calcium fluoride as a white pigment in a quantity of from 1-20 percent by weight. The presence of the calcium fluoride enables an opaque effect to be achieved without reducing the permeability of the filling material to polymerization radiation.
Patients receive cisplatin IV over 1 hour on days 1, 8, 15, 22, 29, and 36 and undergo extended-field radiotherapy daily 5 days a week for 6 weeks followed by brachytherapy. Beginning 4-6 weeks after completion of chemoradiation, patients receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
BACKGROUND: The development of emergency department (ED) triage systems remains challenging in accurately differentiating patients with acute abdominal pain (AAP) who are critical and urgent for surgery due to subjectivity and limitations. We use machine learning models to predict emergency surgical abdominal pain patients in triage, and then compare their performance with conventional Logistic regression models.
METHODS: Using 38 214 patients presenting with acute abdominal pain at Zhongnan Hospital of Wuhan University between March 1, 2014, and March 1, 2022, we identified all adult patients (aged ≥18 years). We utilized routinely available triage data in electronic medical records as predictors, including structured data (eg, triage vital signs, gender, and age) and unstructured data (chief complaints and physical examinations in free-text format). The primary outcome measure was whether emergency surgery was performed. The dataset was randomly sampled, with 80% assigned to the training set and 20% to the test set. We developed 5 machine learning models: Light Gradient Boosting Machine (Light GBM), eXtreme Gradient Boosting (XGBoost), Deep Neural Network (DNN), and Random Forest (RF). Logistic regression (LR) served as the reference model. Model performance was calculated for each model, including the area under the receiver-work characteristic curve (AUC) and net benefit (decision curve), as well as the confusion matrix.
RESULTS: Of all the 38 214 acute abdominal pain patients, 4208 underwent emergency abdominal surgery while 34 006 received non-surgical treatment. In the surgery outcome prediction, all 4 machine learning models outperformed the reference model (eg, AUC, 0.899 [95%CI 0.891-0.903] in the Light GBM vs. 0.885 [95%CI 0.876-0.891] in the reference model), Similarly, most machine learning models exhibited significant improvements in net reclassification compared to the reference model (eg, NRIs of 0.0812[95%CI, 0.055-0.1105] in the XGBoost), with the exception of the RF model. Decision curve analysis shows that across the entire range of thresholds, the net benefits of the XGBoost and the Light GBM models were higher than the reference model. In particular, the Light GBM model performed well in predicting the need for emergency abdominal surgery with higher sensitivity, specificity, and accuracy.
CONCLUSIONS: Machine learning models have demonstrated superior performance in predicting emergency abdominal pain surgery compared to traditional models. Modern machine learning improves clinical triage decisions and ensures that critically needy patients receive priority for emergency resources and timely, effective treatment.
The present invention relates to compositions comprising CpG rich DNA from Pseudomonas aeruginosa. The compositions optionally comprise a cupredoxin. The present invention includes specific CpG DNAs from Pseudomonas aeruginosa that are useful for treating cancer and other conditions in patients. These compositions are optionally in a pharmaceutically acceptable carrier and also optionally comprise a cupredoxin. The present invention further relates to methods to express proteins near cancer cells. These methods may be used to express therapeutic or diagnostic proteins near cancer cells in a patient suffering from cancer or other conditions, and can also be used for diagnosing cancer in a patient. This method uses the gene for azurin from P. aeruginosa as an expression system for azurin or heterologous proteins in P. aeruginosa or heterologous cells.
The exercise intervention will last 16 weeks, comprised of home-based exercise with weekly telephone counselling to encourage participants to continue to exercise, supplemented with 8 supervised exercise sessions (2 sessions per month). Each session will last for an hour. The supervised exercise sessions will be provided by professional exercise specialists twice in the first week in each month throughout the intervention period, an hour each time. Exercise trainers will lead the classes. Each class will include both aerobic exercise and resistance exercise. They are encouraged to do aerobic exercise for at least 150 min weekly at a moderate intensity level, as well as perform resistance exercises alternate day. Participants are also provided an exercise diary, containing details of their weekly prescribed exercises and the scales they have to refer to.
Pulmonary arterial hypertension (PAH) is a complex and fatal cardio-pulmonary vascular disease. Decompensated right ventricular hypertrophy (RVH) caused by cardiomyocyte hypertrophy often leads to fatal heart failure, the leading cause of mortality among patients. Sodium butyrate (SB), a compound known to reduce cardiac hypertrophy, was examined for its potential effect and the underlying mechanism of SB on PAH-RVH. The in vivo study showed that SB alleviated RVH and cardiac dysfunction, as well as improved life span and survival rate in MCT-PAH rats. The in vivo and in vitro experiments showed that SB could attenuate cardiomyocyte hypertrophy by reversing the expressions of H19, let-7g-5p, insulin-like growth factor 1 receptor (IGF1 receptor), and pERK. H19 inhibition restored the level of let-7g-5p and prevented the overexpression of IGF1 receptor and pERK in hypertrophic cardiomyocytes. In addition, dual luciferase assay revealed that H19 demonstrated significant binding with let-7g-5p, acting as its endogenous RNA. Briefly, SB attenuated PAH-RVH by inhibiting the H19 overexpression, restoring the level of let-7g-5p, and hindering IGF1 receptor/ERK activation.
After randomization, participants received Mircette consisting of 150 μg desogestrel (DSG)/20 μg ethinyl estradiol (EE) administered orally as a combination tablet once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE tablet once daily for 5 days (Cycle 2). Participants who completed Cycle 2 then received Kariva, consisting of 150 μg DSG/20 μg EE administered orally as a combination tablet taken once daily for 21 days followed by placebo tablet once daily for 2 days followed by 10 μg EE taken once daily for 5 days (Cycle 3).
Elective laparoscopic ovarian cystectomy is established as the treatment of choice for benign ovarian cysts. The advantages of laparoscopic surgery over conventional open surgery are less pain, shorter recovery time, shorter hospital stay, and consequently faster return to normal activity as well as better cosmetic effects. However, laparoscopic surgery is more challenging compared with open surgery, partly because surgeons must operate in a three-dimensional (3D) space through a two-dimensional (2D) projection on a monitor, which results in loss of depth perception and consequently more cognitive workload on the surgeon. In traditional 2D laparoscopic procedures, the surgeon has to mentally transform and process the 2D image into a 3D image using motion parallax through movement of the laparoscope, relative position of instruments, and shading of light and dark. During the past 3 decades, 3D imaging systems have been introduced in and attempt to improve in-depth perception and spatial orientation during minimally invasive surgery. The anticipated advantages for the surgeon are greater accuracy and speed in manual skills, translating to decreased operative time, a reduced learning curve, and enhanced safety.

Nevertheless, studies, to date, examining the potential advantages and disadvantages of 3D versus 2D imaging systems have produced contradictory results. Moreover, there have been no studies exploring the advantage of 3D imaging system in patients undergoing laparoscopic ovarian cystectomy. The aim of this study was to gain subjective and objective data to determine whether 3D imaging systems in the treatment of ovarian cyst are superior to 2D systems in terms of surgical outcomes.